As shown in Figure 1, both drugs were able to down-regulate survivin expression in all cell lines investigated, which included cells derived from glioblastoma, lymphoma, multiple myeloma, and carcinoma of the breast, colon, and prostate. Here, BIRC5 is linked to lymphoma.